Blockchain Registration Transaction Record

Alzamend Neuro Doses First Patient in Phase II Trial of AL001 for Neurological Disorders

Alzamend Neuro announces dosing of first patient in Phase II trial of AL001, a lithium-based therapeutic for Alzheimer’s, bipolar disorder, MDD, and PTSD. Learn more about this breakthrough treatment here.

Alzamend Neuro Doses First Patient in Phase II Trial of AL001 for Neurological Disorders

This news is significant as AL001 offers a novel approach to treating neurological disorders by improving drug delivery and reducing side effects. If successful, this therapy could transform the treatment landscape for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xf67ca11d38a4e2c38e56a118e0e64d61c0aee03e65eb33034b185ba689a74183
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintbold5LnO-e87d6a5b8949b052ae422bd51f603d53